# CRISPR Therapeutics AG: financial statements, quarterly

CRSP · Nasdaq · CIK 1674416 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crsp.md) · [Financials](/companies/crsp/financials.md) · [Filings](/companies/crsp/filings.md) · [Insiders](/companies/crsp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crsp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-121105.md) | [201 d](/filings/0001193125-26-048957.md) | [0.5](/filings/0000950170-25-064468.md) | [0.5](/filings/0000950170-25-102052.md) | [0.6](/filings/0001193125-25-273337.md) | [35.7 d](/filings/0001193125-26-048957.md) | [0.9](/filings/0001193125-26-204188.md) | [0.9](/filings/0001193125-26-330672.md) | [0.9](/filings/0001193125-25-273337.md) | [0.9 d](/filings/0001193125-26-048957.md) | [1.5](/filings/0001193125-26-204188.md) | [10.2](/filings/0001193125-26-330672.md) |
| Research and development | $m | [90.7](/filings/0000950170-24-121105.md) | [95.1 d](/filings/0001193125-26-048957.md) | [76.2](/filings/0000950170-25-064468.md) | [80.2](/filings/0000950170-25-102052.md) | [82.2](/filings/0001193125-25-273337.md) | [71.7 d](/filings/0001193125-26-048957.md) | [72.5](/filings/0001193125-26-204188.md) | [69.9](/filings/0001193125-26-330672.md) | [58.9](/filings/0001193125-25-273337.md) | [83.5 d](/filings/0001193125-26-048957.md) | [68.6](/filings/0001193125-26-204188.md) | [67.2](/filings/0001193125-26-330672.md) |
| Operating income | $m | [(132)](/filings/0000950170-24-121105.md) | [69.6 d](/filings/0001193125-26-048957.md) | [(141)](/filings/0000950170-25-064468.md) | [(151)](/filings/0000950170-25-102052.md) | [(110)](/filings/0001193125-25-273337.md) | [(64.6) d](/filings/0001193125-26-048957.md) | [(148)](/filings/0001193125-26-204188.md) | [(229)](/filings/0001193125-26-330672.md) | [(132)](/filings/0001193125-25-273337.md) | [(155) d](/filings/0001193125-26-048957.md) | [(130)](/filings/0001193125-26-204188.md) | [(117)](/filings/0001193125-26-330672.md) |
| Income tax | $m | [0.4](/filings/0000950170-24-121105.md) | [0.2 d](/filings/0001193125-26-048957.md) | [0.7](/filings/0000950170-25-064468.md) | [1.3](/filings/0000950170-25-102052.md) | [0.9](/filings/0001193125-25-273337.md) | [0.7 d](/filings/0001193125-26-048957.md) | [1.1](/filings/0001193125-26-204188.md) | [1.3](/filings/0001193125-26-330672.md) | [0.6](/filings/0001193125-25-273337.md) | [0.6 d](/filings/0001193125-26-048957.md) | [0.8](/filings/0001193125-26-204188.md) | [1.0](/filings/0001193125-26-330672.md) |
| Net income | $m | [(112)](/filings/0000950170-24-121105.md) | [89.3 d](/filings/0001193125-26-048957.md) | [(117)](/filings/0001193125-25-273337.md) | [(126)](/filings/0001193125-25-273337.md) | [(85.9)](/filings/0001193125-25-273337.md) | [(37.3) d](/filings/0001193125-26-048957.md) | [(136)](/filings/0001193125-26-330672.md) | [(209)](/filings/0001193125-26-330672.md) | [(106)](/filings/0001193125-25-273337.md) | [(131) d](/filings/0001193125-26-048957.md) | [(123)](/filings/0001193125-26-330672.md) | [(91.2)](/filings/0001193125-26-330672.md) |
| Diluted EPS | $ per share | [(1.41)](/filings/0000950170-24-121105.md) | not reported | [(1.43)](/filings/0000950170-25-064468.md) | [(1.49)](/filings/0000950170-25-102052.md) | [(1.01)](/filings/0001193125-25-273337.md) | not reported | [(1.58)](/filings/0001193125-26-204188.md) | [(2.40)](/filings/0001193125-26-330672.md) | [(1.17)](/filings/0001193125-25-273337.md) | not reported | [(1.28)](/filings/0001193125-26-204188.md) | [(0.94)](/filings/0001193125-26-330672.md) |
| Basic EPS | $ per share | [(1.41)](/filings/0000950170-24-121105.md) | not reported | [(1.43)](/filings/0000950170-25-064468.md) | [(1.49)](/filings/0000950170-25-102052.md) | [(1.01)](/filings/0001193125-25-273337.md) | not reported | [(1.58)](/filings/0001193125-26-204188.md) | [(2.40)](/filings/0001193125-26-330672.md) | [(1.17)](/filings/0001193125-25-273337.md) | not reported | [(1.28)](/filings/0001193125-26-204188.md) | [(0.94)](/filings/0001193125-26-330672.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [528](/filings/0000950170-24-121105.md) | [389](/filings/0001193125-26-048957.md) | [707](/filings/0000950170-25-064468.md) | [484](/filings/0000950170-25-102052.md) | [226](/filings/0001193125-25-273337.md) | [298](/filings/0001193125-26-048957.md) | [235](/filings/0001193125-26-204188.md) | [194](/filings/0001193125-26-330672.md) | [286](/filings/0001193125-25-273337.md) | [348](/filings/0001193125-26-330672.md) | [423](/filings/0001193125-26-204188.md) | [291](/filings/0001193125-26-330672.md) |
| Current assets | $m | [1,761](/filings/0000950170-23-059476.md) | [1,908](/filings/0000950170-25-017899.md) | [2,120](/filings/0000950170-24-055719.md) | [2,010](/filings/0000950170-24-090746.md) | [1,944](/filings/0000950170-24-121105.md) | [1,937](/filings/0001193125-26-048957.md) | [1,868](/filings/0000950170-25-064468.md) | [1,734](/filings/0000950170-25-102052.md) | [1,929](/filings/0001193125-25-273337.md) | [1,986](/filings/0001193125-26-330672.md) | [2,448](/filings/0001193125-26-204188.md) | [2,372](/filings/0001193125-26-330672.md) |
| Total assets | $m | [2,087](/filings/0000950170-23-059476.md) | [2,230](/filings/0000950170-25-017899.md) | [2,439](/filings/0000950170-24-055719.md) | [2,340](/filings/0000950170-24-090746.md) | [2,256](/filings/0000950170-24-121105.md) | [2,242](/filings/0001193125-26-048957.md) | [2,166](/filings/0000950170-25-064468.md) | [2,030](/filings/0000950170-25-102052.md) | [2,245](/filings/0001193125-25-273337.md) | [2,265](/filings/0001193125-26-330672.md) | [2,726](/filings/0001193125-26-204188.md) | [2,651](/filings/0001193125-26-330672.md) |
| Current liabilities | $m | [111](/filings/0000950170-23-059476.md) | [109](/filings/0000950170-25-017899.md) | [119](/filings/0000950170-24-055719.md) | [128](/filings/0000950170-24-090746.md) | [89.8](/filings/0000950170-24-121105.md) | [87.8](/filings/0001193125-26-048957.md) | [119](/filings/0000950170-25-064468.md) | [104](/filings/0000950170-25-102052.md) | [119](/filings/0001193125-25-273337.md) | [149](/filings/0001193125-26-330672.md) | [136](/filings/0001193125-26-204188.md) | [133](/filings/0001193125-26-330672.md) |
| Total liabilities | $m | [359](/filings/0000950170-23-059476.md) | [347](/filings/0000950170-25-017899.md) | [355](/filings/0000950170-24-055719.md) | [359](/filings/0000950170-24-090746.md) | [316](/filings/0000950170-24-121105.md) | [310](/filings/0001193125-26-048957.md) | [337](/filings/0000950170-25-064468.md) | [319](/filings/0000950170-25-102052.md) | [329](/filings/0001193125-25-273337.md) | [343](/filings/0001193125-26-330672.md) | [911](/filings/0001193125-26-204188.md) | [904](/filings/0001193125-26-330672.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-330672.md) | [585](/filings/0001193125-26-204188.md) | [586](/filings/0001193125-26-330672.md) |
| Shareholders' equity | $m | [1,728](/filings/0000950170-24-121105.md) | [1,883](/filings/0001193125-26-048957.md) | [2,084](/filings/0001193125-25-273337.md) | [1,981](/filings/0001193125-25-273337.md) | [1,940](/filings/0001193125-25-273337.md) | [1,932](/filings/0001193125-26-330672.md) | [1,829](/filings/0001193125-26-330672.md) | [1,711](/filings/0001193125-26-330672.md) | [1,916](/filings/0001193125-25-273337.md) | [1,922](/filings/0001193125-26-330672.md) | [1,815](/filings/0001193125-26-330672.md) | [1,747](/filings/0001193125-26-330672.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(39.9) d](/filings/0000950170-24-121105.md) | [(96.1) d](/filings/0001193125-26-048957.md) | [110](/filings/0000950170-25-064468.md) | [(95.6) d](/filings/0000950170-25-102052.md) | [(107) d](/filings/0001193125-25-273337.md) | [(50.0) d](/filings/0001193125-26-048957.md) | [(53.9)](/filings/0001193125-26-204188.md) | [(114) d](/filings/0001193125-26-330672.md) | [(84.6) d](/filings/0001193125-25-273337.md) | [(92.6) d](/filings/0001193125-26-048957.md) | [(109)](/filings/0001193125-26-204188.md) | [(83.5) d](/filings/0001193125-26-330672.md) |
| Capital expenditure | $m | [2.1 d](/filings/0000950170-24-121105.md) | [0.7 d](/filings/0001193125-26-048957.md) | [0.7](/filings/0000950170-25-064468.md) | [0.7 d](/filings/0000950170-25-102052.md) | [0.2 d](/filings/0001193125-25-273337.md) | [0.3 d](/filings/0001193125-26-048957.md) | [0.2](/filings/0001193125-26-204188.md) | [0.1 d](/filings/0001193125-26-330672.md) | [0.1 d](/filings/0001193125-25-273337.md) | [0.5 d](/filings/0001193125-26-048957.md) | [0.5](/filings/0001193125-26-204188.md) | [0.6 d](/filings/0001193125-26-330672.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.0](/filings/0000950170-23-059476.md) | [78.7](/filings/0000950170-24-055719.md) | [79.1](/filings/0000950170-24-090746.md) | [79.4](/filings/0000950170-24-121105.md) | [81.8](/filings/0000950170-25-064468.md) | [84.9](/filings/0000950170-25-102052.md) | [85.2](/filings/0001193125-25-273337.md) | [85.9](/filings/0001193125-26-204188.md) | [87.1](/filings/0001193125-26-330672.md) | [91.3](/filings/0001193125-25-273337.md) | [96.1](/filings/0001193125-26-204188.md) | [96.5](/filings/0001193125-26-330672.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,692,653 at 2026-07-31, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-330672.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.